FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766389926> ?p ?o ?g. }

• W2766389926 endingPage "1755" @default.
• W2766389926 startingPage "1755" @default.
• W2766389926 abstract "Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. The best approach to testing among non-US born residents, particularly those with comorbid conditions, is uncertain.To estimate health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities.Decision analytic tree and Markov cohort simulation model among non-US born residents with no comorbidities, with diabetes, with HIV infection, or with end-stage renal disease (ESRD) using a health care sector perspective with 3% annual discounting. Strategies compared included no testing, tuberculin skin test (TST), interferon gamma release assay (IGRA), confirm positive (initial TST, IGRA only for TST-positive results; both tests positive indicates LTBI), and confirm negative (initial IGRA, then TST for IGRA-negative; any test positive indicates LTBI). All strategies were coupled to treatment with 3 months of self-administered rifapentine and isoniazid.Number needed to test and treat to prevent 1 case of TB reactivation, discounted quality-adjusted life-years (QALYs), discounted lifetime medical costs, and incremental cost-effectiveness ratios (ICERs).Improving health outcomes increased costs, with choice of test dependent on willingness to pay. Strategies ranked by ascending costs and benefits: no testing, confirm positive, TST, IGRA, and confirm negative. The ICERs varied by non-US born patient risk group: patients with no comorbidities, IGRA was likely cost-effective at $83 000/QALY; patients with diabetes, both confirm positive ($53 000/QALY) and IGRA ($120 000/QALY) were likely cost-effective; patients with HIV, confirm negative was clearly preferred ($63 000/QALY); and patients with ESRD, no testing was cost-effective. Increased LTBI prevalence and reduced return for TST reading improved IGRA's relative performance. In 10 000 probabilistic simulations among non-US born patients with no comorbidities, with diabetes, and with HIV, some form of testing was virtually always cost-effective. These simulations highlight the uncertainty of test choice for non-US born patients with no comorbidities and non-US born patients with diabetes, but strategies including IGRA were preferred in over 60% of simulations for all non-US born populations except those with ESRD.Testing for and treating LTBI among non-US born residents with and without selected comorbidities is likely cost-effective except among those with ESRD in whom competing risks of death limit benefits. Strategies including IGRA fell below a $100 000/QALY willingness-to-pay threshold for non-US born patients with no comorbidities, patients with diabetes, and patients with HIV." @default.
• W2766389926 created "2017-11-10" @default.
• W2766389926 creator A5036782519 @default.
• W2766389926 creator A5054840982 @default.
• W2766389926 creator A5059135593 @default.
• W2766389926 creator A5060660336 @default.
• W2766389926 creator A5062268434 @default.
• W2766389926 creator A5063282541 @default.
• W2766389926 date "2017-12-01" @default.
• W2766389926 modified "2023-10-16" @default.
• W2766389926 title "Cost-effectiveness of Testing and Treatment for Latent Tuberculosis Infection in Residents Born Outside the United States With and Without Medical Comorbidities in a Simulation Model" @default.
• W2766389926 cites W104219690 @default.
• W2766389926 cites W1518167791 @default.
• W2766389926 cites W154273085 @default.
• W2766389926 cites W1730777739 @default.
• W2766389926 cites W1830381349 @default.
• W2766389926 cites W1980075079 @default.
• W2766389926 cites W2019547690 @default.
• W2766389926 cites W2023940135 @default.
• W2766389926 cites W2031034414 @default.
• W2766389926 cites W2031290587 @default.
• W2766389926 cites W2031741473 @default.
• W2766389926 cites W2034298502 @default.
• W2766389926 cites W2049404409 @default.
• W2766389926 cites W2049958950 @default.
• W2766389926 cites W2056072007 @default.
• W2766389926 cites W2058056848 @default.
• W2766389926 cites W2090669065 @default.
• W2766389926 cites W2112720518 @default.
• W2766389926 cites W2114609571 @default.
• W2766389926 cites W2127497497 @default.
• W2766389926 cites W2141090053 @default.
• W2766389926 cites W2148232746 @default.
• W2766389926 cites W2154625247 @default.
• W2766389926 cites W2156207025 @default.
• W2766389926 cites W2158530640 @default.
• W2766389926 cites W2162514859 @default.
• W2766389926 cites W2171188971 @default.
• W2766389926 cites W2271596670 @default.
• W2766389926 cites W2465612624 @default.
• W2766389926 cites W2559832962 @default.
• W2766389926 cites W2916589395 @default.
• W2766389926 cites W4229629337 @default.
• W2766389926 cites W4248739489 @default.
• W2766389926 cites W80887403 @default.
• W2766389926 doi "https://doi.org/10.1001/jamainternmed.2017.3941" @default.
• W2766389926 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5808933" @default.
• W2766389926 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29049814" @default.
• W2766389926 hasPublicationYear "2017" @default.
• W2766389926 type Work @default.
• W2766389926 sameAs 2766389926 @default.
• W2766389926 citedByCount "49" @default.
• W2766389926 countsByYear W27663899262017 @default.
• W2766389926 countsByYear W27663899262018 @default.
• W2766389926 countsByYear W27663899262019 @default.
• W2766389926 countsByYear W27663899262020 @default.
• W2766389926 countsByYear W27663899262021 @default.
• W2766389926 countsByYear W27663899262022 @default.
• W2766389926 countsByYear W27663899262023 @default.
• W2766389926 crossrefType "journal-article" @default.
• W2766389926 hasAuthorship W2766389926A5036782519 @default.
• W2766389926 hasAuthorship W2766389926A5054840982 @default.
• W2766389926 hasAuthorship W2766389926A5059135593 @default.
• W2766389926 hasAuthorship W2766389926A5060660336 @default.
• W2766389926 hasAuthorship W2766389926A5062268434 @default.
• W2766389926 hasAuthorship W2766389926A5063282541 @default.
• W2766389926 hasBestOaLocation W27663899261 @default.
• W2766389926 hasConcept C112930515 @default.
• W2766389926 hasConcept C126322002 @default.
• W2766389926 hasConcept C142724271 @default.
• W2766389926 hasConcept C2776247216 @default.
• W2766389926 hasConcept C2777975735 @default.
• W2766389926 hasConcept C2779806340 @default.
• W2766389926 hasConcept C2780277586 @default.
• W2766389926 hasConcept C2780639635 @default.
• W2766389926 hasConcept C2781069245 @default.
• W2766389926 hasConcept C3019080777 @default.
• W2766389926 hasConcept C71924100 @default.
• W2766389926 hasConcept C72563966 @default.
• W2766389926 hasConceptScore W2766389926C112930515 @default.
• W2766389926 hasConceptScore W2766389926C126322002 @default.
• W2766389926 hasConceptScore W2766389926C142724271 @default.
• W2766389926 hasConceptScore W2766389926C2776247216 @default.
• W2766389926 hasConceptScore W2766389926C2777975735 @default.
• W2766389926 hasConceptScore W2766389926C2779806340 @default.
• W2766389926 hasConceptScore W2766389926C2780277586 @default.
• W2766389926 hasConceptScore W2766389926C2780639635 @default.
• W2766389926 hasConceptScore W2766389926C2781069245 @default.
• W2766389926 hasConceptScore W2766389926C3019080777 @default.
• W2766389926 hasConceptScore W2766389926C71924100 @default.
• W2766389926 hasConceptScore W2766389926C72563966 @default.
• W2766389926 hasIssue "12" @default.
• W2766389926 hasLocation W27663899261 @default.
• W2766389926 hasLocation W27663899262 @default.
• W2766389926 hasLocation W27663899263 @default.
• W2766389926 hasLocation W27663899264 @default.
• W2766389926 hasOpenAccess W2766389926 @default.
• W2766389926 hasPrimaryLocation W27663899261 @default.

• next